NeuLogiq® Platform Helps Confirm No Evidence of Psychotomimetic, Hallucinatory, or Dissociative Effects in a Phase 1b Study of a Novel Neuroplastogen Developed for Major Depressive Disorder

Delix Therapeutics presented data for their novel neuroplastogen zalsupindole (DLX-001) at the 2026 American Society of Clinical Neuropharmacology (ASCP) Conference including NeuLogiq® Platform data which supports at-home administration in future trials BELFAST, Northern Ireland, May 28,...